$INTI
Inhibitor Therapeutics, Inc.

2013 Q4 Form 10-K Financial Statement

#000119312514144186 Filed on April 15, 2014

View on sec.gov

Income Statement

Concept 2013 Q4 2013 2012 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $200.0K $820.0K $240.0K
YoY Change -16.67% 46.43% -47.83%
% of Gross Profit
Research & Development $20.00K $1.065M
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $210.0K $2.000M $240.0K
YoY Change -12.5% 256.68% -47.83%
Operating Profit -$2.000M
YoY Change 256.68%
Interest Expense $0.00 $1.923K $100.0K
YoY Change -100.0% -97.6% -112.5%
% of Operating Profit
Other Income/Expense, Net -$100.0K
YoY Change -110.87%
Pretax Income -$220.0K -$1.840M -$220.0K
YoY Change 0.0% -1068.42% 37.5%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$220.0K -$1.835M -$220.0K
YoY Change 0.0% -1084.65% 37.5%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10
Diluted Earnings Per Share -$0.01 -$0.10 -$0.01
COMMON SHARES
Basic Shares Outstanding 18.89M shares 17.94M shares
Diluted Shares Outstanding 17.94M shares

Balance Sheet

Concept 2013 Q4 2013 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00 $860.0K
YoY Change -100.0% -100.0% -34.85%
Cash & Equivalents $217.00 $0.00 $857.7K
Short-Term Investments $0.00
Other Short-Term Assets $10.00K $78.73K
YoY Change -87.5% -1.58%
Inventory
Prepaid Expenses $10.00K
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $10.22K $10.00K $936.4K
YoY Change -98.91% -98.94% -33.11%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $10.22K $10.00K $936.4K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $10.22K $10.00K $936.4K
YoY Change -98.91% -98.94% -33.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $287.1K $290.0K $368.6K
YoY Change -22.12% -21.62% -7.85%
Accrued Expenses $0.00 $0.00 $190.0K
YoY Change -100.0% -100.0% 11.76%
Deferred Revenue
YoY Change
Short-Term Debt $70.00K $70.00K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $776.1K $780.0K $560.0K
YoY Change 38.59% 39.29% -1.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $0.00 $510.0K
YoY Change -100.0% -100.0% -5.56%
Total Long-Term Liabilities $0.00 $0.00 $510.0K
YoY Change -100.0% -100.0% -57.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $776.1K $780.0K $560.0K
Total Long-Term Liabilities $0.00 $0.00 $510.0K
Total Liabilities $776.1K $780.0K $1.069M
YoY Change -27.42% -27.1% -39.59%
SHAREHOLDERS EQUITY
Retained Earnings -$28.25M -$26.41M
YoY Change 6.95%
Common Stock $1.889K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$765.8K -$770.0K -$132.8K
YoY Change
Total Liabilities & Shareholders Equity $10.22K $10.00K $936.4K
YoY Change -98.91% -98.94% -33.11%

Cashflow Statement

Concept 2013 Q4 2013 2012 Q4
OPERATING ACTIVITIES
Net Income -$220.0K -$1.835M -$220.0K
YoY Change 0.0% -1084.65% 37.5%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$170.0K -$1.224M -$60.00K
YoY Change 183.33% 163.56% -140.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 170.0K 366.1K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -170.0K -1.224M -60.00K
Cash From Investing Activities 0.000
Cash From Financing Activities 170.0K 366.1K 0.000
Net Change In Cash 0.000 -857.5K -60.00K
YoY Change -100.0% 84.7% -104.84%
FREE CASH FLOW
Cash From Operating Activities -$170.0K -$1.224M -$60.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18888971 shares
CY2013Q2 dei Entity Public Float
EntityPublicFloat
152743
CY2008Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
500000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.02
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
245443 shares
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-369150
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1321968
CY2012Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15560504 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15560504 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.02
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
245443 shares
CY2012Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Liabilities Subject To Compromise
LiabilitiesSubjectToCompromise
509266
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.02
CY2012Q4 us-gaap Liabilities Subject To Compromise Other Liabilities
LiabilitiesSubjectToCompromiseOtherLiabilities
63500
CY2012Q4 us-gaap Liabilities Subject To Compromise Accounts Payable And Accrued Liabilities
LiabilitiesSubjectToCompromiseAccountsPayableAndAccruedLiabilities
422316
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
62652
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26279815
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
368613
CY2012Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16047183
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
559953
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-132784
CY2012Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
191340
CY2012Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26412599
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
936435
CY2012Q4 us-gaap Liabilities
Liabilities
1069219
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
CY2012Q4 us-gaap Interest Payable Current
InterestPayableCurrent
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Assets Current
AssetsCurrent
936435
CY2012Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
CY2012Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15994583
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16047183
CY2012Q4 us-gaap Assets
Assets
936435
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
857702
CY2012Q4 us-gaap Escrow Deposit
EscrowDeposit
75000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
62652
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
52600
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
78733
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
CY2012Q4 hppi Liabilities Subject To Compromise Priority Claims
LiabilitiesSubjectToCompromisePriorityClaims
23450
CY2013Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18888971 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
975000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18888971 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2013Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Liabilities Subject To Compromise
LiabilitiesSubjectToCompromise
CY2013Q4 us-gaap Liabilities Subject To Compromise Other Liabilities
LiabilitiesSubjectToCompromiseOtherLiabilities
CY2013Q4 us-gaap Liabilities Subject To Compromise Accounts Payable And Accrued Liabilities
LiabilitiesSubjectToCompromiseAccountsPayableAndAccruedLiabilities
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27479913
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287072
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.85
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
68428
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
756783
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
776053
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-765836
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
CY2013Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
366130
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28247655
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1889
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10217
CY2013Q4 us-gaap Liabilities
Liabilities
776053
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
52500
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1923
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets Current
AssetsCurrent
10217
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
346801
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
407398
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
756783
CY2013Q4 us-gaap Assets
Assets
10217
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
217
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
0
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2584
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
CY2013Q4 hppi Net Operating Loss Amount Used To Offset Against Taxable Income
NetOperatingLossAmountUsedToOffsetAgainstTaxableIncome
35000
CY2013Q4 hppi Liabilities Subject To Compromise Priority Claims
LiabilitiesSubjectToCompromisePriorityClaims
CY2013Q4 hppi Working Capital Advances From Affiliates
WorkingCapitalAdvancesFromAffiliates
100000
CY2013Q4 hppi Maximum Expected Equity Fund From Public Private And Other Financing Transaction
MaximumExpectedEquityFundFromPublicPrivateAndOtherFinancingTransaction
5000000
CY2013Q1 hppi Percentage Of Issued And Outstanding Shares Of Common Stock
PercentageOfIssuedAndOutstandingSharesOfCommonStock
1.00 pure
CY2013Q1 hppi Ownership Exchanged For Assets Contributed
OwnershipExchangedForAssetsContributed
0.90 pure
CY2012Q3 hppi Debt Instrument Written Off
DebtInstrumentWrittenOff
666667
CY2012Q3 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
625000 shares
CY2012Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
666667
CY2012Q3 hppi Market Value Of Restricted Shares Issued
MarketValueOfRestrictedSharesIssued
13000
CY2013Q2 hppi Period Consider For Average Equity Stock Price Calculation Per Share
PeriodConsiderForAverageEquityStockPriceCalculationPerShare
P30D
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17940586 shares
CY2013 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
CY2013 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
shares
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17940586 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1223615
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17940586 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
245443 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 16pt"> <b><i>Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 4pt"> The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
CY2013 us-gaap Revenues
Revenues
CY2013 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-1835056
CY2013 us-gaap Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1
DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1
166676
CY2013 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
152000
CY2013 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
CY2013 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-68733
CY2013 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-1999809
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-1835056
CY2013 us-gaap Dilutive Securities
DilutiveSecurities
CY2013 us-gaap Notes Issued1
NotesIssued1
68428
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1050004
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
817316
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
366130
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
691007
CY2013 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
46645
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-857485
CY2013 us-gaap Interest Expense
InterestExpense
1923
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-63688
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-627319
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1065169
CY2013 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
366130
CY2013 us-gaap Depreciation
Depreciation
0
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2013 us-gaap Operating Expenses
OperatingExpenses
1999809
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2012 us-gaap Revenues
Revenues
CY2012 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
186366
CY2012 us-gaap Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1
DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1
747036
CY2013 hppi Stock Issuance Costs
StockIssuanceCosts
CY2013 hppi In Process Research And Development Paid In Stock
InProcessResearchAndDevelopmentPaidInStock
1020004
CY2012 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-527
CY2012 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
CY2013 hppi Reorganization And Other Expenses
ReorganizationAndOtherExpenses
117324
CY2013 hppi Net Cash Provided By Operating Activities Before Reorganization Items
NetCashProvidedByOperatingActivitiesBeforeReorganizationItems
-699674
CY2013 hppi Increase Decrease In Liabilities Subject To Compromise
IncreaseDecreaseInLiabilitiesSubjectToCompromise
-357265
CY2013 hppi Gain Loss On Reorganization
GainLossOnReorganization
166676
CY2013 hppi Stock Payment In Lieu Of Cash
StockPaymentInLieuOfCash
152000
CY2013 hppi Bankruptcy Claims Settlement In Cash
BankruptcyClaimsSettlementInCash
357265
CY2013 hppi Bankruptcy Claims Settlement In Equity
BankruptcyClaimsSettlementInEquity
152000
CY2013 hppi Period Consider For Average Equity Stock Price Calculation Per Share
PeriodConsiderForAverageEquityStockPriceCalculationPerShare
P30D
CY2013 hppi Sharebased Compensation Arrangement Purchase Price Of Common Stock Percent Related To Specific Voting Stock Percentage
SharebasedCompensationArrangementPurchasePriceOfCommonStockPercentRelatedToSpecificVotingStockPercentage
1.10 pure
CY2013 hppi Minimum Specified Voting Stock Percentage Under Incentive Stock Plan
MinimumSpecifiedVotingStockPercentageUnderIncentiveStockPlan
0.10 pure
CY2013 hppi Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Related To Specific Voting Stock Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodRelatedToSpecificVotingStockPercentage
P5Y
CY2013 hppi Supply And License Agreement Term Duration From First Commercial Transaction
SupplyAndLicenseAgreementTermDurationFromFirstCommercialTransaction
P10Y
CY2013 hppi Gain Loss On Reorganization And Extinguishment Of Debt
GainLossOnReorganizationAndExtinguishmentOfDebt
166676
CY2013 hppi Deposit Reclassified To Preferred Stock
DepositReclassifiedToPreferredStock
30000
CY2013 hppi Percentage Of Issued And Outstanding Common Stock
PercentageOfIssuedAndOutstandingCommonStock
0.30 pure
CY2013 hppi Maximum Reimbursement Expenses Allowed
MaximumReimbursementExpensesAllowed
100000
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13646638 shares
CY2012 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13646638 shares
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-464266
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.01
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13646638 shares
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2012 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
666667
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-560670
CY2012 us-gaap Net Income Loss
NetIncomeLoss
186366
CY2012 us-gaap Dilutive Securities
DilutiveSecurities
CY2012 us-gaap Notes Issued1
NotesIssued1
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
560670
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
347
CY2012 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-34492
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-464266
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-347
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
CY2012 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
CY2012 us-gaap Depreciation
Depreciation
0
CY2012 us-gaap Operating Expenses
OperatingExpenses
560670
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2012 hppi Stock Issuance Costs
StockIssuanceCosts
50000
CY2012 hppi In Process Research And Development Paid In Stock
InProcessResearchAndDevelopmentPaidInStock
CY2012 hppi Net Cash Provided By Operating Activities Before Reorganization Items
NetCashProvidedByOperatingActivitiesBeforeReorganizationItems
-464266
CY2012 hppi Increase Decrease In Liabilities Subject To Compromise
IncreaseDecreaseInLiabilitiesSubjectToCompromise
CY2012 hppi Stock Payment In Lieu Of Cash
StockPaymentInLieuOfCash
CY2012 hppi Gain Loss On Reorganization And Extinguishment Of Debt
GainLossOnReorganizationAndExtinguishmentOfDebt
747036
CY2012 hppi Deposit Reclassified To Preferred Stock
DepositReclassifiedToPreferredStock
CY2012 hppi Reorganization Realized Gain
ReorganizationRealizedGain
80369

Files In Submission

Name View Source Status
0001193125-14-144186-index-headers.html Edgar Link pending
0001193125-14-144186-index.html Edgar Link pending
0001193125-14-144186.txt Edgar Link pending
0001193125-14-144186-xbrl.zip Edgar Link pending
d650079d10k.htm Edgar Link pending
d650079dex311.htm Edgar Link pending
d650079dex312.htm Edgar Link pending
d650079dex321.htm Edgar Link pending
d650079dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hppi-20131231.xml Edgar Link completed
hppi-20131231.xsd Edgar Link pending
hppi-20131231_cal.xml Edgar Link unprocessable
hppi-20131231_def.xml Edgar Link unprocessable
hppi-20131231_lab.xml Edgar Link unprocessable
hppi-20131231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending